• The Future History of Payments

    The Future History of Payments

    A new report from Kapronasia sponsored by Finastra looks at the key opportunities and challenges in a rapidly changing global payments environment.
  • Financial Inclusion Accelerated

    Financial Inclusion Accelerated

    A new report from Kapronasia and Vocalink looks at how real-time payments are impacting financial inclusion around the world and what lies ahead.
  • Research Calendar 2018

    Research Calendar 2018

    The Kapronasia 2018 Research Calendar has been published, contact us to receive a copy and subscribe.
  • 1
  • 2
  • 3

Latest Reports

Even as the entire financial industry changes rapidly, nowhere has the change been as evident as in the payments segment. Around the world, banks, consumers, and businesses are making a shift in the way they exchange value.
Most of the research into real-time payments has focused on potential new revenue streams and business models for banks to serve traditional retail and commercial customers. Although this research is valuable, it overlooks an essential segment of the population: the underbanked and financially excluded. Until now.
After an eventful year with many notable developments in the burgeoning field of fintech, our 8th annual Top-10 Asia Pacific Fintech Trends Report, released in conjunction with the webinar, features an in depth analysis of the 10 most important fintech trends to look out for in Asia this year.


March 13, 2018 - Mar 15, 2018
Money 20/20 Asia Singapore
March 21, 2018 - Mar 22, 2018
Payments Summit 2018 - Helsinki
March 27, 2018 - Mar 28, 2018
MoneyLive: Digital Banking APAC 2018
May 03, 2018 - May 04, 2018
Seamless Asia Singapore
June 04, 2018 - Jun 06, 2018
Money 20/20 Europe - Amsterdam
September 19, 2018 - Sep 20, 2018
Global Payments Summit KL
October 22, 2018 - Oct 23, 2018
Sibos Sydney
November 14, 2018 - Nov 16, 2018
Money 2020 China

Kapronasia is a leading provider of financial industry market research and consulting covering fintech, payments, banking, capital markets and blockchain.


Research From our offices across the region, we provide clients with the key insight and research they need to understand the market trends and challenges. Our research reports are used by numerous clients across the globe to make better business decisions about their Asia strategy.


Consulting We work closely with clients to better understand their business challenges and find lasting and value creating solutions. We have worked with some of the financial industry's largest players to help them re-define their business and drive growth.

A quick note on the GlaxoSmithKline inquiry in China

Written by Zennon Kapron 25 Jul 2013 25 Jul 2013

Although it's completely outside of our area of focus (beyond being China related), we have been getting a number of questions from clients and Kapronasia followers about the situation at GlaxoSmithKline (GSK) and so I thought we should give a bit of background, our position, and the relevance to China's FSI. 


If you haven't been following the news, very briefly, the Chinese government has accused GSK of bribing doctors and hospitals to take their products in exchange for trips and cash incentives allegedly facilitated by a local travel company. Shocker...  Some thoughts:

Firstly, this practice is growing increasingly rare, but is not-unheard of. In China, multinationals for years have operated through middlemen to, for lack of a better word, bribe local authorities, regulators and potential customers. Whether the intermediary was a marketing company, travel agent, or consultant, the agent would give the MNC a bit of arm's length to conduct business in what was once the only way of doing business in China.

Secondly, I find it very hard to believe that senior management outside of China did not know that this was happening. Bribes are rife in the pharma industry throughout the world and China has been known to be corrupt. If you can seriously say that you had no idea it was happening, you should be in a different job. To say that you/the company don't condone it, ok, not aware of it, impossible - don't throw your people under the bus and claim ignorance.

Thirdly, this is part of a Chinese government crackdown on corruption in China that is unlikely to abate anytime soon. If you are operating somehow illegally here, this is a sign that you need to change and change soon as both national and global companies are being monitored and investigated.

Finally, that vigilance is not limited to the pharma industry. Having been involved in the financial technology space here in China for nearly 10 years, we have seen graft and corruption. Whether it's revenue smoothing, over-inflated expenses or R&D centre visits ('really, you do your R&D in the Maldives??'), it has and does happen.

However, it is changing. Relationships are still going to be important. You need to be trusted to do business here, but don't get relationships confused with corruption. Will a $75 bottle of wine from California that you brought over be appreciated by a potential client? Yes of course, and it will help develop that relationship as it would with any other friend or acquaintance.

And you should think about it from that perspective: would you pay for a friend to go to London so that he would be a better friend? Well I suppose you could, but I would guess that's not a very deep friendship based on mutual trust. Much better to spend the time to get to know the client, show your commitment, and as trite as it sounds, become a 'trusted advisor'. Reasonable gifts do have their place as they do in any relationship. 

In a very brief conclusion, China is not an easy place to do business, but it is an important place to do business and you need to come in with your eyes open. Awareness is key. Complicity is not. 


Kapronasia Newsletter

Sign up for our email list and stay up to date with our latest insights.